Having trouble accessing articles? Reset your cache.

Japanese approvals include a global first for Roche's tissue-agnostic cancer drug

Among the four Japanese drug approvals announced on Tuesday was the global first for tissue-agnostic cancer therapy Rozlytrek entrectinib from Roche.

Japan's Ministry of Health, Labour and Welfare (MHLW) approved the inhibitor of ROS1, TrkA, TrkB, TrkC and ALK from Roche

Read the full 412 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers